Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | The use of CRISPR-Cas9 technology in the development of T cell therapies

Alessio Nahmad, PhD, Tel Aviv University, Tel Aviv, Israel, describes the role and applications of CRISPR-Cas9-based genome editing in the development of CAR T-cell and T cell receptor (TCR) therapies. The aim is often to ablate specific genes that can reduce efficiency of the T cell product such the TCR genes. For example, ablating TCR genes can improve efficiency and reduce toxicity. In addition, ablating certain genes, such as PD-1, can reduce cellular exhaustion. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.